By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The Translational Genomics Research Institute’s TGen Drug Development (TD2) arm will use Horizon Discovery’s isogenic cell lines in a partnership focused on developing pharmacogenomic tools for use in cancer drug research services, TGen said today.

The partners will use Horizon Discovery Services’ panel of more than 200 genetically-defined X-Man human isogenic cell lines in TD2’s comprehensive pre-clinical service before it conducts certain in-house clinical trials.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.

Dec
12
Sponsored by
Illumina

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.